Total immunotherapy for Hodgkin lymphoma
Résumé
The anti-CD30 antibody-drug conjugate brentuximab vedotin and the programmed cell death 1 (PD-1) monoclonal antibodies nivolumab and pembrolizumab have dramatically improved outcomes for patients with relapsed or refractory classic Hodgkin lymphoma. With the goal of improving the depth and duration of remissions with these drugs, combination strategies investigating various combination partners are underway, including conventional chemotherapy and other checkpoint inhibitors. Trials investigating the combination of nivolumab and brentuximab vedotin in first and second-line settings showed a significant improvement in complete response rate compared with treatment with either nivolumab or brentuximab vedotin alone, suggesting the potential of this approach.
Fichier principal
Houot_Total immunotherapy for Hodgkin lymphoma_accepted.pdf (151.7 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...